Metabolic therapy for the treatment of ischemic heart disease: reality and expectations (Q37012951)

17 August 2017

1 reference

title

Metabolic therapy for the treatment of ischemic heart disease: reality and expectations (English)

1 reference

17 August 2017

1 reference

coronary artery disease

1 reference

Wei Wang

1

1 reference

17 August 2017

Gary D Lopaschuk

series ordinal

2

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Expert Review of Cardiovascular Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

5

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

1123-1134

1 reference

Partial fatty acid oxidation inhibitors for stable angina

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Cardiac fatty acid uptake and transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Transport of fatty acids across membranes by the diffusion mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Cytoplasmic fatty acid-binding proteins: Their structure and genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Cellular fatty acid-binding proteins: their function and physiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Myocardial substrate metabolism in the normal and failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Metabolic and genetic regulation of cardiac energy substrate preference

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

The role of the myocardial sodium-hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Regulation of myocardial glucose uptake and transport during ischemia and energetic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Malonyl-CoA decarboxylase inhibition as a novel approach to treat ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Plasma fatty acid levels in infants and adults after myocardial ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Amiloride delays the ischemia-induced rise in cytosolic free calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Glucose-insulin-potassium techniques in cardiac surgery: historical overview and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Insulin attenuates the systemic inflammatory response in endotoxemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Glucose-insulin-potassium therapy in the era of coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Glucose-insulin-potassium solution for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Impact of high glucose/high insulin and dichloroacetate treatment on carbohydrate oxidation and functional recovery after low-flow ischemia and reperfusion in the isolated perfused rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

The effect of Oxfenicine on cardiac carbohydrate metabolism in intact dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Changes in myocardial substrate and energy metabolism by S-(4)-hydroxyphenylglycine and an N-(6)-derivative of adenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Limitation of myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Impaired oxidation of debrisoquine in patients with perhexiline liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Modification of left ventricular hypertrophy by chronic etomixir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

3-(2,2,2-Trimethylhydrazinium)propionate (THP)--a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.6.1123

10.1586/14779072.5.6.1123

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference